<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05089487</url>
  </required_header>
  <id_info>
    <org_study_id>OVERALP II E</org_study_id>
    <nct_id>NCT05089487</nct_id>
  </id_info>
  <brief_title>Nocturnal Oxygenation and Sleep-related Breathing Disorders During the First Night of a Stay at 2500m of High Altitude in Patients With Precapillary Pulmonary Hypertension</brief_title>
  <official_title>The Impact of Hypoxia on Patients With Precapillary Pulmonary Hypertension and Treatment of Adverse Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The impact of hypoxia at 2500m of high altitude on sleep in patients with precapillary&#xD;
      pulmonary hypertension&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 18, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 16, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients free of severe hypoxemia</measure>
    <time_frame>30 hours</time_frame>
    <description>Proportion of patients free of severe hypoxemia (defined as oxygenation (SpO2)&lt;80% for &gt;30 min) without oxygen therapy during nocturnal rest at 2500 m vs. 490 m</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nocturnal oxygenation</measure>
    <time_frame>30 hours</time_frame>
    <description>Difference in mean nocturnal oxygenation (SpO2) 2500 m of high altitude vs 490 m low altitude</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen desaturation index</measure>
    <time_frame>30 hours</time_frame>
    <description>Difference in oxygen desaturation index sleeping at 2500 m high altitude vs 490 m low altitude</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periodic breathing</measure>
    <time_frame>30 hours</time_frame>
    <description>Difference in time spent with periodic breathing in patients sleeping at 2500 m of high altitude vs 490 m low altitude</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nocturnal transcutaneous carbon dioxide tension</measure>
    <time_frame>30 hours</time_frame>
    <description>Difference in nocturnal transcutaneous carbon dioxide tension in patients sleeping at 2500 m of high altitude vs 490 m low altitude</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>30 hours</time_frame>
    <description>Subjective sleep quality Visual Analogue Scale score 2500 m high altitude vs 490 m low altitude</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent awake during the night</measure>
    <time_frame>30 hours</time_frame>
    <description>Subjective time spent awake during the night high altitude vs 490 m low altitude</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral tissue deoxygenation</measure>
    <time_frame>30 hours</time_frame>
    <description>Proportion of patients free of severe cerebral tissue deoxygenation (drop in cerebral tissue oxygen saturation &gt;5%) without oxygen therapy during a night at 2500 vs. 490 m</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral tissue oxygen saturation awake</measure>
    <time_frame>30 hours</time_frame>
    <description>Difference in cerebral tissue oxygen saturation awake in patients with precapillary pulmonary hypertension at 2500m of high altitude without supplemental oxygen vs. low altitude</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral tissue oxygen saturation during sleep without oxygen</measure>
    <time_frame>30 hours</time_frame>
    <description>Difference in cerebral tissue oxygen saturation during sleep in patients with precapillary pulmonary hypertension at 2500m of high altitude without supplemental oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral tissue oxygen saturation during sleep with oxygen</measure>
    <time_frame>30 hours</time_frame>
    <description>Difference in cerebral tissue oxygen saturation during sleep in patients with precapillary pulmonary hypertension at 2500m of high altitude with supplemental oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral oxygen desaturation index without oxygen</measure>
    <time_frame>30 hours</time_frame>
    <description>Difference in the cerebral oxygen desaturation index in patients with precapillary pulmonary hypertension at 2500m of high altitude without supplemental oxygen vs. low altitude</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral oxygen desaturation index with oxygen</measure>
    <time_frame>30 hours</time_frame>
    <description>Difference in the cerebral oxygen desaturation index in patients with precapillary pulmonary hypertension at 2500m of high altitude under supplemental oxygen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral tissue oxygen saturation between different sleep stages</measure>
    <time_frame>30 hours</time_frame>
    <description>Changes in the cerebral tissue oxygen saturation between different sleep stages at 2500 m compared to low altitude.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>High Altitude Pulmonary Hypertension</condition>
  <condition>Sleep</condition>
  <arm_group>
    <arm_group_label>High altitude 2500 m above sea level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low altitude 470 m above sea level</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nocturnal rest (sleep study)</intervention_name>
    <description>Proportion of patients free of severe hypoxemia without oxygen therapy during nocturnal rest .</description>
    <arm_group_label>High altitude 2500 m above sea level</arm_group_label>
    <arm_group_label>Low altitude 470 m above sea level</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent as documented by signature (Appendix Informed Consent Form)&#xD;
&#xD;
          -  PH class I (PAH) or IV (CTEPH) diagnosed according to guidelines: mean pulmonary&#xD;
             artery pressure &gt;20 mmHg, pulmonary vascular resistance ≥3 wood units, pulmonary&#xD;
             arterial wedge pressure ≤15 mmHg during baseline measures at the diagnostic&#xD;
             right-heart catheterization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  resting partial pressure of oxygen &lt;8 kilopascal at Zurich at 490 m low altitude&#xD;
&#xD;
          -  exposure to an altitude &gt;1000 m for ≥3 nights during the last 2 weeks before the study&#xD;
&#xD;
          -  inability to follow the procedures of the study&#xD;
&#xD;
          -  other clinically significant concomitant end-stage disease (e.g., renal failure,&#xD;
             hepatic dysfunction)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Silvia Ulrich, Prof. Dr.</last_name>
    <phone>+41442552220</phone>
    <email>silvia.ulrich@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simon Schnieder, MA</last_name>
    <phone>+41442552220</phone>
    <email>simonrafael.schneider@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Ulrich, Prof. Dr.</last_name>
      <phone>+41442552220</phone>
      <email>silvia.ulrich@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Simon Schnieder, MA</last_name>
      <phone>+41442552220</phone>
      <email>simonrafael.schneider@usz.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

